IL223845A - Use of 1hmgb as a biomarker of intestinal inflammatory conditions, non-invasive methods for his diagnosis of faecal samples and kit - Google Patents

Use of 1hmgb as a biomarker of intestinal inflammatory conditions, non-invasive methods for his diagnosis of faecal samples and kit

Info

Publication number
IL223845A
IL223845A IL223845A IL22384512A IL223845A IL 223845 A IL223845 A IL 223845A IL 223845 A IL223845 A IL 223845A IL 22384512 A IL22384512 A IL 22384512A IL 223845 A IL223845 A IL 223845A
Authority
IL
Israel
Prior art keywords
hmgb1
disease
patients
inflammatory
protein
Prior art date
Application number
IL223845A
Other languages
English (en)
Hebrew (he)
Inventor
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Original Assignee
D M G Italia S R L
Salvatore Cucchiara
Laura Stronati
Roberta Vitali
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D M G Italia S R L, Salvatore Cucchiara, Laura Stronati, Roberta Vitali filed Critical D M G Italia S R L
Publication of IL223845A publication Critical patent/IL223845A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL223845A 2010-08-05 2012-12-24 Use of 1hmgb as a biomarker of intestinal inflammatory conditions, non-invasive methods for his diagnosis of faecal samples and kit IL223845A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM2010A000442A IT1406051B1 (it) 2010-08-05 2010-08-05 Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
PCT/IT2011/000276 WO2012017466A1 (en) 2010-08-05 2011-08-01 Use of hmgb1 as' a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof

Publications (1)

Publication Number Publication Date
IL223845A true IL223845A (en) 2016-06-30

Family

ID=43739596

Family Applications (1)

Application Number Title Priority Date Filing Date
IL223845A IL223845A (en) 2010-08-05 2012-12-24 Use of 1hmgb as a biomarker of intestinal inflammatory conditions, non-invasive methods for his diagnosis of faecal samples and kit

Country Status (14)

Country Link
US (1) US20130137123A1 (https=)
EP (1) EP2601525A1 (https=)
JP (1) JP2013534313A (https=)
CN (1) CN103069276A (https=)
AU (1) AU2011287193B2 (https=)
BR (1) BR112013002145A2 (https=)
CA (1) CA2807107C (https=)
CL (1) CL2013000223A1 (https=)
EA (1) EA201390197A1 (https=)
IL (1) IL223845A (https=)
IT (1) IT1406051B1 (https=)
MX (1) MX2013001327A (https=)
PE (1) PE20131062A1 (https=)
WO (1) WO2012017466A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015067913A1 (en) 2013-11-07 2015-05-14 Diagnodus Limited Biomarkers
DK2968443T3 (da) 2013-03-15 2021-12-06 Protagonist Therapeutics Inc Hepcidinanaloger og anvendelser deraf
PT3143037T (pt) 2014-05-16 2021-09-24 Protagonist Therapeutics Inc Antagonistas peptídicos tioéter de integrina alfa4beta7
US9624268B2 (en) 2014-07-17 2017-04-18 Protagonist Therapeutics, Inc. Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
US20190002503A1 (en) 2015-12-30 2019-01-03 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
PL3622082T3 (pl) 2017-05-12 2023-07-31 Evonik Operations Gmbh Sposób wykrywania chorób wywołanych przez C. perfringens w stadzie ptaków
IT201700083044A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della gelsolina come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
IT201700083055A1 (it) 2017-07-20 2019-01-20 Laura Stronati “uso della proteina inibitore 2 della dissociazione di rho gdp come marcatore diagnostico e prognostico delle malattie infiammatorie intestinali”
EP3749345A4 (en) 2018-02-08 2022-04-06 Protagonist Therapeutics, Inc. CONJUGATED HEPCIDIN MIMETICS
US12031991B2 (en) * 2018-03-02 2024-07-09 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals
CN109030817A (zh) * 2018-07-04 2018-12-18 长沙都正医学检验有限责任公司 Hmgb1检测试剂盒及其制备方法
TW202019948A (zh) 2018-07-12 2020-06-01 美商領導醫療有限公司 介白素-23受體之肽抑制劑及其治療發炎疾病之用途
DK3894863T3 (en) 2018-12-14 2023-02-20 Evonik Operations Gmbh In vitro-fremgangsmåde til påvisning af aviær intestinal dysbiose
US11684653B2 (en) * 2019-03-06 2023-06-27 The Cleveland Clinic Foundation Compositions and method for reducing virulence of microorganisms
HRP20250769T1 (hr) 2020-01-15 2025-08-29 Janssen Biotech, Inc. Peptidni inhibitori receptora za interleukin-23 i njihova uporaba u liječenju upalnih bolesti
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
AU2021383828A1 (en) 2020-11-20 2023-07-06 Janssen Pharmaceutica Nv Compositions of peptide inhibitors of interleukin-23 receptor
WO2023288019A2 (en) 2021-07-14 2023-01-19 Janssen Biotech, Inc. Lipidated peptide inhibitors of interleukin-23 receptor
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822078B2 (en) * 1996-07-17 2004-11-23 Kaneka Corp. Diagnostic drugs for autoimmune diseases
US6355623B2 (en) * 1998-09-24 2002-03-12 Hopital-Sainte-Justine Method of treating IBD/Crohn's disease and related conditions wherein drug metabolite levels in host blood cells determine subsequent dosage
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7700307B2 (en) * 2003-03-08 2010-04-20 Auvation Limited Mitochondrial stress-70 protein markers for colorectal cancer
US7585504B2 (en) * 2004-10-22 2009-09-08 Medimmune, Llc High affinity antibodies against HMGB1 and methods of use thereof
US20090297546A1 (en) * 2006-12-20 2009-12-03 Shino-Test Corporation Avian-derived antibody capable of binding specifically to human hmgb1, immunological determination method for human hmgb1, and immunological determination reagent for human hmgb1
EA201000131A1 (ru) * 2007-08-02 2010-08-30 АйЭсЭс ИММЬЮН СИСТЕМ СТИМУЛЕЙШН АБ Диагностика, определение стадии и мониторинг воспалительного заболевания кишечника
US7879553B2 (en) * 2008-03-14 2011-02-01 Exagen Diagnostics, Inc. Biomarkers for inflammatory bowel disease and irritable bowel syndrome

Also Published As

Publication number Publication date
AU2011287193B2 (en) 2015-08-13
WO2012017466A8 (en) 2013-07-11
EA201390197A1 (ru) 2013-06-28
JP2013534313A (ja) 2013-09-02
CN103069276A (zh) 2013-04-24
AU2011287193A1 (en) 2013-06-13
ITRM20100442A1 (it) 2012-02-06
WO2012017466A1 (en) 2012-02-09
IT1406051B1 (it) 2014-02-06
MX2013001327A (es) 2013-03-08
CA2807107C (en) 2017-01-03
PE20131062A1 (es) 2013-10-16
CL2013000223A1 (es) 2014-03-28
CA2807107A1 (en) 2012-02-09
EP2601525A1 (en) 2013-06-12
BR112013002145A2 (pt) 2016-05-24
US20130137123A1 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
CA2807107C (en) Use of hmgb1 as a biological marker of bowel inflammatory conditions, non-invasive method for its detection in fecal samples and kit thereof
Audo et al. Rheumatoid arthritis is associated with increased gut permeability and bacterial translocation that are reversed by inflammation control
Kaiser et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome
Iskandar et al. Biomarkers in inflammatory bowel disease: current practices and recent advances
D'angelo et al. Calprotectin in daily practice: where do we stand in 2017?
van de Logt et al. S 100 A 12: A noninvasive marker of inflammation in inflammatory bowel disease
KR20100063052A (ko) 염증성 장 질환의 진단, 단계 구분 및 모니터링 방법
Jessen et al. Level of tumor necrosis factor production by stimulated blood mononuclear cells can be used to predict response of patients with inflammatory bowel diseases to infliximab
Klimczak et al. The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity
Stascheit et al. Calprotectin as potential novel biomarker in myasthenia gravis
Ge et al. Monitoring of intestinal inflammation and prediction of recurrence in ulcerative colitis
Turkay et al. Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update
Kamounah et al. Seronegative patients with primary Sjögren's syndrome and non-pSS sicca test positive for anti-SSA/Ro52 and-Ro60 in saliva
Hamdy et al. Matrix metalloproteinase-3 as a marker of subclinical activity in rheumatoid arthritis patients: Relation to ultrasonographic activity
Huong et al. Role of Calprotectin, IL-6, and CRP in distinguishing between inflammatory bowel disease and diarrhea predominant irritable bowel syndrome
Chernoff et al. Determination of the minimally important difference (MID) in multi-biomarker disease activity (MBDA) test scores: impact of diurnal and daily biomarker variation patterns on MBDA scores
US20230074127A1 (en) Test and in vitro diagnosis of irritable bowel syndrome
Abdelati et al. Patterns of interstitial lung disease in Egyptian patients with systemic sclerosis: Relation to disease parameters
Lee et al. Fecal S100A12 is associated with future hospitalization and step-up of medical treatment in patients with Crohn’s disease in clinical remission: a pilot study
CN114270191B (zh) 炎症性肠病诊断方法、诊断探针和诊断试剂盒
Wang et al. Association of serum anti-carbamylated protein antibodies with disease activity and bone loss in rheumatoid arthritis
Toğrol et al. The significance of coeliac disease antibodies in patients with ankylosing spondylitis: a case-controlled study
US20220214357A1 (en) Method of determining the probability of inflammatory bowel disease in a subject being ulcerative colitis or crohn's disease
KR20130136964A (ko) 창자 감염성 병태의 생물학적 마커로서 hmgb1의 용도, 대변 샘플에서 그의 검출을 위한 비침습적 방법 및 키트
Şimşek et al. Fecal S100A12 as a Biomarker in Behcet’s Disease

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed